Is hepatitis virus resistance to antiviral drugs a threat?

Gastroenterology

Volumn 142, Issue 6, 2012, Pages 1369-1372

  Pawlotsky, Jean Michel ^a,b  

^a UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^b INSERM U955   (France)

Author keywords

DAA; direct acting antiviral; HAART; HBV; HCV; hepatitis B virus; hepatitis C virus; highly active antiretroviral therapy; HIV; human immunodeficiency virus; IFN; interferon

Indexed keywords

ADEFOVIR; ALPHA INTERFERON; ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; EMTRICITABINE; ENTECAVIR; LAMIVUDINE; PEGINTERFERON; RIBAVIRIN; RNA DIRECTED RNA POLYMERASE; TENOFOVIR;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANTIVIRAL SUSCEPTIBILITY; CAUSE OF DEATH; DISEASE COURSE; FOLLOW UP; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HEPATITIS VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; LONG TERM CARE; MONOTHERAPY; NOTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT FAILURE; VIRUS REPLICATION; VIRUS RESISTANCE;

EID: 84860273164     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2011.12.060     Document Type: Article

References (23)

1. F. Clavel, A.J. Hance HIV drug resistance N Engl J Med 350 2004 1023 1035
2. C.L. Lai, J. Dienstag, E. Schiff Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B Clin Infect Dis 36 2003 687 696
3. S.J. Hadziyannis, N.C. Tassopoulos, E.J. Heathcote Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years Gastroenterology 131 2006 1743 1751
4. P. Lampertico, M. Vigano, E. Manenti Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients Gastroenterology 133 2007 1445 1451
5. L.C. Wang, E.Q. Chen, J. Cao De novo combination of lamivudine and adefovir versus entecavir monotherapy for the treatment of naive HBeAg-negative chronic hepatitis B patients Hepatol Int 5 2011 671 676
6. S. Villet, C. Pichoud, G. Billioud Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure J Hepatol 48 2008 747 755
7. D.J. Tenney, K.A. Pokornowski, R.E. Rose Entecavir maintains a high genetic barrier to HBV resistance through 6 years in naive patients J Hepatol 50 Suppl 1 2009 S10
8. P. Marcellin, E.J. Heathcote, A. Corsa No detectable resistance to tenofovir disoproxil fumarate (TDF) following up to 240 weeks of treatment Hepatology 54 Suppl 2011 480A
9. European Association for the Study of Liver Diseases EASL Clinical Practice Guidelines: management of chronic hepatitis B J Hepatol 50 2009 227 242
10. A.S. Lok, B.J. McMahon Chronic hepatitis B: update 2009 Hepatology 50 2009 661 662
11. F. Zoulim, S. Locarnini Hepatitis B virus resistance to nucleos(t)ide analogues Gastroenterology 137 2009 1593 1608 e1-2
12. A.U. Neumann, N.P. Lam, H. Dahari Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy Science 282 1998 103 107
13. J.M. Pawlotsky Genetic heterogeneity and properties of hepatitis C virus Acta Gastroenterol Belg 61 1998 189 191
14. L. Rong, H. Dahari, R.M. Ribeiro Rapid emergence of protease inhibitor resistance in hepatitis C virus Sci Transl Med 2 2010 30ra32
15. S. Chevaliez, C. Rodriguez, A. Soulier Molecular characterization of HCV resistance to telaprevir by means of ultra-deep pyrosequencing: preexisting resistant variants and dynamics of resistant populations J Hepatol 54 Suppl 1 2011 S30
16. J.M. Pawlotsky Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus Hepatology 53 2011 1742 1751
17. B.R. Bacon, S.C. Gordon, E. Lawitz HCV RESPOND-2 final results: high sustained virologic response among genotype 1 previous nonresponders and relapsers to peginterferon/ribavirin when retreated with boceprevir plus PegIntron (peginterferon alfa-2b)/ribavirin Hepatology 52 Suppl 2010 430A
18. F. Poordad, J. McCone Jr, B.R. Bacon Boceprevir for untreated chronic HCV genotype 1 infection N Engl J Med 364 2011 1195 1206
19. S. Zeuzem, P. Andreone, S. Pol Telaprevir for retreatment of HCV infection N Engl J Med 364 2011 2417 2428
20. S. Zeuzem, M.S. Sulkowski, F. Zoulim Long-term follow-up of patients with chronic hepatitis C treated with telaprevir in combination with peginterferon alfa-2a and ribavirin: interim analysis of the EXTEND study Hepatology 52 Suppl 2010 436A
21. A.S. Lok, D. Gardiner, E. Lawitz Quadruple therapy with BMS-790052, BMS-650032 and peg-IFN/RBV for 24 weeks results in 100% SVR12 in HCV genotype 1 null responders J Hepatol 54 Suppl 1 2011 S536
22. K. Chayama, S. Takahashi, Y. Kawakami Dual oral combination therapy with the NS5A inhibitor BMS-790052 and the NS3 protease inhibitor BMS-650032 achieved 90% sustained virologic response (SVR12) in HCV genotype 1b-infected null responders Hepatology 54 Suppl 2011 1428A
23. E.J. Gane, C.A. Stedman, R.H. Hyland Once daily PSI-7977 plus RBV: pegylated interferon-alfa not required for complete rapid viral response in treatment-naive patients with HCV GT2 or GT3 Hepatology 54 Suppl 2011 377A